Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd

About this trial

The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Eligibility criteria

Qualifiers

Fully understand the study and voluntarily sign the informed consent form;

Male or female 18~75 years of age;

Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;

Life expectancy ≥ 3 months;

Disqualifiers

Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Trial design

Treatments tested in this trial

  • ZG006
  • Topotecan

Treatment groups

420 Participants
are divided into 2 treatment groups